HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited

HUTCHMED (China) ( ($HK:0013) ) has issued an update. HUTCHMED announced that it will present new preclinical and clinical data at the American Ass...

HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026

Jefferies analyst Glynis Johnson maintained a Hold rating on Holcim on April 3 and set a price target of CHF72.60. Johnson covers the Consumer Cycl...

Jefferies Reaffirms Their Hold Rating on Holcim (0QKY)

Jefferies analyst Edison Lee maintained a Buy rating on China Mobile on April 3 and set a price target of HK$97.46. According to TipRanks, Lee is a...

Jefferies Sticks to Their Buy Rating for China Mobile (0941)

The latest announcement is out from Healthier Choices Management ( ($HCMC) ). On March 27, 2026, Healthier Choices Management Corp. entered into a ...

Healthier Choices Management Secures New $5 Million Credit Facility

First Shanghai Securities analyst maintained a Buy rating on China Mobile yesterday and set a price target of HK$108.00. Currently, the analyst con...

China Mobile (0941) Receives a Buy from First Shanghai Securities

In a report released yesterday, Glynis Johnson from Jefferies maintained a Hold rating on Holcim, with a price target of CHF73.20. The company’s sh...

In a report released yesterday, from Bank of China maintained a Buy rating on China Mobile, with a price target of HK$98.54. The company’s shares c...

China Mobile (0941) Gets a Buy from Bank of China

HUTCHMED (China) ( ($HK:0013) ) has shared an update. HUTCHMED has begun a registrational Phase III clinical trial in China of its investigational ...

HUTCHMED Launches Phase III Trial of BTK Inhibitor HMPL-760 in Chinese Lymphoma Patients

In a report released on March 20, Prieto Luis from Kepler Capital maintained a Buy rating on Holcim, with a price target of CHF90.00. The company’s...

New Buy Rating for Holcim (0QKY), the Basic Materials Giant

In a report released today, Julian Radlinger from UBS maintained a Buy rating on Holcim, with a price target of CHF93.00. Radlinger covers the Basi...

In a report released on March 13, from SPDB maintained a Buy rating on HUTCHMED (China) , with a price target of HK$28.00. The company’s shares clo...

HUTCHMED (China)  (HCM) Receives a Buy from SPDB

Kepler Capital analyst Prieto Luis maintained a Buy rating on Holcim on March 12 and set a price target of CHF90.00. The company’s shares closed ye...

Holcim (0QKY) Receives a Buy from Kepler Capital

In a report released yesterday, from CICC maintained a Buy rating on HUTCHMED (China) , with a price target of HK$30.00. The company’s shares close...

HUTCHMED (China)  (HCM) Gets a Buy from CICC

BOCOM International Holdings Company analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of HK$36.60. The company’...

HUTCHMED (China)  (HCM) Receives a Buy from BOCOM International Holdings Company

An update from HUTCHMED (China) ( ($HK:0013) ) is now available. HUTCHMED has vested a total of 726,317 ordinary shares under its Long Term Incenti...

Market Cap	$2.69B	P/E Ratio	36.49
52W High	$19.50	52W Low	$11.51
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	29.3%	52W Position	43.2%
Overall Score	35	Value Score	40
Quality Score	--	Technical Score	30

EPS Current Est	$0.41	EPS Next Est	$0.93
EPS Growth Est	+126.8%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HCM	$14.96	-2.79%	29.75K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HCM	$14.96	-2.8%	29.75K
3
4
5
6

HCM

HCM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get HUTCHMED (China) Limited Data in Excel

Get HUTCHMED (China) Limited Data in Excel